



Tuesday, November 21, 2006

Dear Fellow Shareholders of Nutra Pharma,

This past quarter was filled with a number of milestones for the Company. I am excited to have the opportunity to share some of these recent accomplishments with you as we progress into the final few months of the year.

I would like to take the opportunity to welcome Dr. Dorothy Bray, Ph.D. to the ReceptoPharm Scientific Advisory Board. We are honored to have Dr. Bray join our team. Prior to founding ImmunoClin Ltd., Dr. Bray served as the Director of HIV Clinical Development at GlaxoSmithKline (GSK) with global responsibility for their clinical trials program. GSK holds approximately 40% of the world-wide drug market in HIV/AIDS. Dr. Bray's clinical development experience and knowledge will be important to the success of our drug discovery initiatives in the fourth quarter and in 2007.

As many of you know, ReceptoPharm received approval by the London Ethics Committee to begin our Phase IIb human clinical trials for the treatment of AMN. This Phase IIb trial is expected to begin within the 4th quarter.

In September, Designer Diagnostics completed its registration with the Food and Drug Administration (FDA) for exporting its NonTuberculosis Mycobacterium (NTM) Test Kits. This not only allows Designer Diagnostics to sell the Test Kit internationally, but also allows the Company to sell and distribute the Test Kit within the United States for research purposes. In addition, the Company is submitting its 510(k) application to the FDA for substantial equivalence. Approval will allow Designer Diagnostics to sell its NTM Test Kits within the United States to physicians and laboratories for use with patients.

Many of our shareholders have been asking about the progress with our Tuberculosis Test Kits. I am pleased to say that our team at Designer Diagnostics has discovered a significant improvement to our original Test Kit technology. Unfortunately, this design change means that our testing will take longer than expected, but we believe that these changes are well worth the extra few months. Designer Diagnostics plans to have the updated test kits in hospital trials within the first quarter of 2007.

I would like to note that Nutra Pharma received some very positive press in July's issue of Business 2.0. If you have not had a chance to review this article, the link is listed on our homepage at [www.NutraPharma.com](http://www.NutraPharma.com).

As always, we are constantly striving to provide our shareholders with the most up-to-date information and news about the Company. If you haven't already signed up for our e-mail alerts, please do so by visiting [www.NutraPharma.com](http://www.NutraPharma.com). Our e-mail alerts system ensures that you will receive news and announcements as soon as they become available.

I look forward to continuing our progress in the final quarter of 2006. If you have any questions about our Company, I invite you to contact our Investor Relations hotline toll-free at (877) 895-5647.

Sincerely yours,

Rik J. Deitsch  
Chairman and Chief Executive Officer  
Nutra Pharma Corporation  
Stock Symbol: NPHC